Make a note
$Scynexis(SCYX.US$ -- SCY-247's IND-enabling activities continue to progress, with initiation
of Phase I anticipated in the second half of 2024
-- Clinical study reports for the FURI, CARES and NATURE trials in
refractory invasive fungal infections remain on track for delivery to GSK
in mid 2024, which would trigger a $10 million development milestone
payment to SCYNEXIS
-- SCYNEXIS ended Q1 2024 with cash, cash equivalents and investments of
$94.2 million and projects a cash runway of more than two years
of Phase I anticipated in the second half of 2024
-- Clinical study reports for the FURI, CARES and NATURE trials in
refractory invasive fungal infections remain on track for delivery to GSK
in mid 2024, which would trigger a $10 million development milestone
payment to SCYNEXIS
-- SCYNEXIS ended Q1 2024 with cash, cash equivalents and investments of
$94.2 million and projects a cash runway of more than two years
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment